39 related articles for article (PubMed ID: 9834240)
1. A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.
Notari M; Neviani P; Santhanam R; Blaser BW; Chang JS; Galietta A; Willis AE; Roy DC; Caligiuri MA; Marcucci G; Perrotti D
Blood; 2006 Mar; 107(6):2507-16. PubMed ID: 16293596
[TBL] [Abstract][Full Text] [Related]
2. Magnetic Nanoparticles PCR Enzyme-Linked Gene Assay for Quantitative Detection of BCR/ABL Fusion Gene in Chronic Myelogenous Leukemia.
Manthawornsiri Y; Polpanich D; Yamkamon V; Thiramanas R; Hongeng S; Rerkamnuaychoke B; Jootar S; Tangboriboonrat P; Jangpatarapongsa K
J Clin Lab Anal; 2016 Sep; 30(5):534-42. PubMed ID: 26667895
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of BCR::ABL (P210) mRNA levels detected by dPCR and qPCR methods in patients with chronic myeloid leukemia].
Gao HL; Hao Y; Chen WM; Li LD; Wang X; Qin YZ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2023 Nov; 44(11):906-910. PubMed ID: 38185519
[No Abstract] [Full Text] [Related]
4. Zinc as a potential regulator of the BCR-ABL oncogene in chronic myelocytic leukemia cells.
Zhu B; Sun L; Li Z; Shang P; Yang C; Li K; Li J; Zhi Q; Hua Z
J Trace Elem Med Biol; 2024 May; 83():127407. PubMed ID: 38325182
[TBL] [Abstract][Full Text] [Related]
5. Bcr-Abl regulation of sphingomyelin synthase 1 reveals a novel oncogenic-driven mechanism of protein up-regulation.
Moorthi S; Burns TA; Yu GQ; Luberto C
FASEB J; 2018 Aug; 32(8):4270-4283. PubMed ID: 29533737
[TBL] [Abstract][Full Text] [Related]
6. Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells.
Guerzoni C; Bardini M; Mariani SA; Ferrari-Amorotti G; Neviani P; Panno ML; Zhang Y; Martinez R; Perrotti D; Calabretta B
Blood; 2006 May; 107(10):4080-9. PubMed ID: 16418324
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterisation of malignant cells using RT-PCR on single flow-sorted cells.
Rasmussen T; Honoré L; Johnsen HE
Med Oncol; 1998 Jul; 15(2):96-102. PubMed ID: 9789216
[TBL] [Abstract][Full Text] [Related]
8. Masked antisense: a molecular configuration for discriminating similar RNA targets.
Stocks MR; Rabbitts TH
EMBO Rep; 2000 Jul; 1(1):59-64. PubMed ID: 11256626
[TBL] [Abstract][Full Text] [Related]
9. CML and the WHO: Why?
Berman E; Shah NP; Deninger M; Altman JK; Amaya M; Begna K; Bhatia R; Chan O; Collins R; Curtin P; DeAngelo DJ; Drazer M; Maness L; Metheny L; Mohan S; Moore J; Oehler V; Pratz K; Pusic I; Rose M; Shomali W; Smith BD; Styler M; Sweet K; Talpaz M; Tanaka T; Tantravahi S; Tsai S; Vaughn J; Welborn J; Yang D; Mauro M; Cortes J; Radich J; Druker B
J Clin Oncol; 2024 Mar; 42(9):984-986. PubMed ID: 38086008
[No Abstract] [Full Text] [Related]
10. Project Confirm: Accelerated Drug Approvals for CML-Letter.
Beumer JH; Salamone SJ
Clin Cancer Res; 2024 Jan; 30(1):235-236. PubMed ID: 38178775
[No Abstract] [Full Text] [Related]
11. Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts.
Sillaber C; Mayerhofer M; Agis H; Sagaster V; Mannhalter C; Sperr WR; Geissler K; Valent P
Wien Klin Wochenschr; 2003 Aug; 115(13-14):485-504. PubMed ID: 13677268
[TBL] [Abstract][Full Text] [Related]
12. Antisense cancer therapy: the state of the science.
Kushner DM; Silverman RH
Curr Oncol Rep; 2000 Jan; 2(1):23-30. PubMed ID: 11122821
[TBL] [Abstract][Full Text] [Related]
13. PKR stimulates NF-kappaB irrespective of its kinase function by interacting with the IkappaB kinase complex.
Bonnet MC; Weil R; Dam E; Hovanessian AG; Meurs EF
Mol Cell Biol; 2000 Jul; 20(13):4532-42. PubMed ID: 10848580
[TBL] [Abstract][Full Text] [Related]
14. 2',5'-Oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cells.
Maran A; Waller CF; Paranjape JM; Li G; Xiao W; Zhang K; Kalaycio ME; Maitra RK; Lichtin AE; Brugger W; Torrence PF; Silverman RH
Blood; 1998 Dec; 92(11):4336-43. PubMed ID: 9834240
[TBL] [Abstract][Full Text] [Related]
15. Antisense locked nucleic acids efficiently suppress BCR/ABL and induce cell growth decline and apoptosis in leukemic cells.
Rapozzi V; Cogoi S; Xodo LE
Mol Cancer Ther; 2006 Jul; 5(7):1683-92. PubMed ID: 16891454
[TBL] [Abstract][Full Text] [Related]
16. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
[TBL] [Abstract][Full Text] [Related]
17. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
Skórski T; Szczylik C; Malaguarnera L; Calabretta B
Folia Histochem Cytobiol; 1991; 29(3):85-9. PubMed ID: 1794439
[TBL] [Abstract][Full Text] [Related]
18. Antisense inhibition of P210 bcr-abl in chronic myeloid leukemia.
Vaerman JL; Lewalle P; Martiat P
Stem Cells; 1993 Oct; 11 Suppl 3():89-95. PubMed ID: 8298481
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
